BPC-157: Research, Studies & Structure

What is BPC-157?

BPC-157 is a 15-amino-acid research peptide. Selected animal injury studies and a two-person human safety pilot explore different questions; neither establishes treatment benefit for injured patients.

Biological role or research focus

Experimental tissue-repair research.

A tendon-cell experiment cannot establish recovery time, pain relief, or a reliable injury treatment in people.

Role reference: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗

Names you may encounter

BPC 157 · BPC157

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity: Experimental pentadecapeptide
Main research area: Tendon and tissue biology
Evidence featured: Rat tendon-cell study
Source check: October 4, 2026

Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗

Molecular structure

⤢ Enlarge 2D

2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 9941957 ↗

Mechanism & research rationale

One proposed pathway involves changing growth-hormone receptor expression in tendon fibroblasts. This offers a cellular hypothesis for repair research without establishing how an injured human tendon responds.

Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗

Research context & status

This profile covers experimental tissue biology. The linked experiment does not provide an established clinical use, recovery timetable, or validated combination with TB-500. Human clinical claims need their own controlled evidence.

Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗

What does the evidence show?

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Rat tendon-cell study · 2014

Growth-hormone receptor experiment

Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.

Population / model: Fibroblasts isolated from rat Achilles tendons.
Study design: Cell-culture experiments measured growth-hormone receptor expression and responses to growth hormone.
Main finding: BPC-157 increased receptor expression, and the treated cells showed a greater proliferative response to growth hormone.
Limits & context: A change in isolated cells is a possible mechanism, not a measured improvement in human tendon strength, pain, return to sport, or long-term safety.

Read PubMed abstract ↗Publisher paper ↗Free full text ↗

Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗

Animal + cell study · 2003

Achilles tendon transection model

Did tissue and functional measures change after a surgically created tendon injury?

Population / model: Rats with transected Achilles tendons, with additional cultured tendon-cell experiments.
Study design: Controlled injury model with functional, mechanical, microscopic, and gross assessments over 14 days.
Main finding: The treated animals had better reported tendon mechanics, functional scores, and tissue organization than controls. Cell experiments also examined responses to an inhibitor of cell growth.
How to read it: This paper connects tissue observations with mechanical and functional measurements within a rat model.
Limits & context: An acute surgical injury in rats differs from human tendinopathy or rehabilitation. These findings do not establish a human recovery time, effective clinical treatment, or long-term safety.

Read PubMed abstract ↗Publisher paper ↗

Source: Staresinic et al. · Journal of Orthopaedic Research · 2003 ↗

Animal study · 2010

Medial collateral ligament healing

Was the repair signal also observed in a ligament injury model?

Population / model: Rats after surgical transection of the medial collateral ligament.
Study design: Controlled experiments with different administration routes and follow-up extending to 90 days.
Main finding: The authors reported improvements in functional, mechanical, gross, and histological measures of ligament healing.
How to read it: A ligament model broadens the preclinical questions beyond the earlier tendon experiment.
Limits & context: This remains animal evidence. Several routes studied in a model do not establish equivalent exposure, benefit, or safety in people.

Read PubMed abstract ↗Publisher paper ↗

Source: Cerovecki et al. · Journal of Orthopaedic Research · 2010 ↗

Uncontrolled human pilot · 2025

BPC-157 · two-person safety pilot

What can the recent intravenous pilot establish?

Population / model: Two adults aged 58 and 68 who had both received intravenous BPC-157 before the study.
Study design: Single private-clinic pilot with blood tests, vital signs, and reported symptoms over three days; no comparator.
Main finding: No reported side effects or measurable changes in the tested organ-function biomarkers were observed during the short monitoring period.
How to read it: Two previously exposed participants provide a very limited observation, not evidence of general safety.
Limits & context: The study cannot detect uncommon or delayed harms, establish injury-healing efficacy, or validate research-use products. The authors’ broad safety conclusion exceeds what this design can establish. Larger controlled studies and pharmaceutical-quality identity checks remain necessary.

Read PubMed abstract ↗

Source: BPC-157 · two-person safety pilot · 2025 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Search additional PubMed records ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Safety & precautions

Safety evidence & remaining uncertainty

FDA flags limited safety information. The tendon-cell paper cannot measure systemic adverse effects, immune reactions, or long-term risks. A vendor purity result would answer a different question from clinical safety.

Source: FDA · Peptide compounding safety concerns ↗

Human pilot does not establish safety

The recent pilot monitored only two previously exposed adults for three days. It cannot exclude delayed or uncommon harms and did not test injury-healing benefit.

Source: BPC-157 · two-person safety pilot · 2025 ↗

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

What are people discussing?

Fouad Abiad Media

Separating perceived peptide effects from changed habits

The speakers name several peptides while discussing how changes in nutrition, sleep, and training can accompany perceived benefits. This is a discussion of experience and confounding factors, not a controlled comparison.

Question to take to the evidence

Did a study isolate the peptide’s effect from simultaneous changes in behavior?

▶ Watch 14:11–15:40 ↗

Caption excerpt reviewed · Claims not independently verified · 2026-10-04
Original episode: BURN FAT FASTER WITH MOTS C | Josh Holyfield | Real Bodybuilding Podcast

Watch the source discussions

78 matching video records · 8 with captions indexed.

Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.